Number: GOG 9924 Principal Investigator: Mutch, David
Title: A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib and Carboplatin in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: I Disease Site: Multiple Sites
Participating Site(s):
Contact: 800-600-3606 or

The purpose of this study is to see what dose of the anti-cancer drug bortezomib can be given with carboplatin in the treatment of your cancer. We will check this by giving this drug and carboplatin, another anti-cancer drug, directly into your abdomen. One of the goals of this study is to determine how bortezomib is absorbed and distributed in your body when administered with carboplatin, directly into the abdominal cavity. A second goal is to determine the appropriate dose of bortezomib for treating your type of cancer when given with carboplatin. Another goal of the study is to evaluate the effectiveness and side effects of this drug combination when given directly into the abdomen.
More Information:
Internal Protocol Documents (requires Siteman administrative database password)